Market capitalization | $4.22m |
Enterprise Value | $820.00k |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 13.67 |
P/S ratio (TTM) P/S ratio | 70.33 |
P/B ratio (TTM) P/B ratio | 1.62 |
Revenue growth (TTM) Revenue growth | -67.76% |
Revenue (TTM) Revenue | $60.00k |
As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.
2 Analysts have issued a Sonnet BioTherapeutics Holdings Inc forecast:
2 Analysts have issued a Sonnet BioTherapeutics Holdings Inc forecast:
Sep '23 |
+/-
%
|
||
Revenue | 0.15 0.15 |
57%
57%
|
|
Gross Profit | 0.07 0.07 |
73%
73%
|
|
EBITDA | -18 -18 |
36%
36%
|
EBIT (Operating Income) EBIT | -19 -19 |
36%
36%
|
Net Profit | -19 -19 |
37%
37%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Sonnet BioTherapeutics Holdings, Inc. engages in the development of biologic drugs with enhanced single or bispecific mechanisms. Its technology utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The company was founded on April 1, 2020 and is headquartered in Princeton, New Jersey.
Head office | United States |
CEO | Pankaj Mohan |
Employees | 12 |
Founded | 2011 |
Website | www.sonnetbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.